Cutler Group LP Altimmune, Inc. Transaction History

Cutler Group LP

$307 Million
Q1 2024

A detailed history of Cutler Group LP transactions in Altimmune, Inc. stock. As of the latest transaction made, Cutler Group LP holds 500 shares of ALT stock, worth $4,340. This represents 0.0% of its overall portfolio holdings.

Number of Shares

500

Previous 2,200 77.27%

Holding current value

$4,340

Previous $24,000 79.17%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 19, 2024	SELL	$8.22 - $13.81 $13,974 - $23,477	-1,700 Reduced 77.27%	500 $5,000
Q4 2023 Jan 18, 2024	BUY	$2.14 - $11.62 $1,498 - $8,133	700 Added 46.67%	2,200 $24,000
Q3 2023 Nov 07, 2023	SELL	$2.4 - $3.45 $2,160 - $3,105	-900 Reduced 37.5%	1,500 $3,000
Q2 2023 Jul 18, 2023	SELL	$3.45 - $5.97 $24,840 - $42,984	-7,200 Reduced 75.0%	2,400 $8,000
Q1 2023 May 01, 2023	BUY	$4.19 - $16.83 $29,749 - $119,492	7,100 Added 284.0%	9,600 $40,000
Q4 2022 Feb 07, 2023	SELL	$8.74 - $16.45 $201,553 - $379,353	-23,061 Reduced 90.22%	2,500 $41,000
Q3 2022 Oct 25, 2022	BUY	$10.67 - $22.41 $272,735 - $572,822	25,561 New	25,561 $326,000
Q1 2022 Apr 14, 2022	SELL	$5.9 - $9.45 $5,310 - $8,505	-900 Closed	0 $0
Q4 2021 Jan 18, 2022	SELL	$8.69 - $12.48 $31,284 - $44,928	-3,600 Reduced 80.0%	900 $8,000
Q3 2021 Oct 26, 2021	BUY	$8.43 - $16.81 $35,237 - $70,265	4,180 Added 1306.25%	4,500 $50,000
Q1 2021 Apr 26, 2021	SELL	$12.71 - $24.31 $26,945 - $51,537	-2,120 Reduced 86.89%	320 $4,000
Q4 2020 Jan 21, 2021	SELL	$7.84 - $14.22 $7,369 - $13,366	-940 Reduced 27.81%	2,440 $27,000
Q3 2020 Oct 27, 2020	BUY	$9.93 - $33.26 $2,780 - $9,312	280 Added 9.03%	3,380 $44,000
Q2 2020 Jul 22, 2020	BUY	$2.9 - $10.71 $8,700 - $32,130	3,000 Added 3000.0%	3,100 $33,000
Q1 2020 May 07, 2020	BUY	$1.69 - $3.8 $169 - $380	100 New	100 $0

Others Institutions Holding ALT

# of Institutions

186

Shares Held

39.3M

Call Options Held

913K

Put Options Held

743K

View Full List

About Altimmune, Inc.

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $426M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

More about ALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.

Account